Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) FCF Margin (2018 - 2026)

10x Genomics' FCF Margin history spans 8 years, with the latest figure at 24.51% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 2356.0% to 24.51% in Q4 2025 year-over-year; TTM through Dec 2025 was 21.13%, a 2026.0% increase, with the full-year FY2025 number at 21.13%, up 2026.0% from a year prior.
  • FCF Margin hit 24.51% in Q4 2025 for 10x Genomics, down from 31.24% in the prior quarter.
  • Over the last five years, FCF Margin for TXG hit a ceiling of 36.74% in Q4 2023 and a floor of 73.71% in Q3 2021.
  • Historically, FCF Margin has averaged 7.89% across 5 years, with a median of 2.76% in 2024.
  • Biggest five-year swings in FCF Margin: surged 12084bps in 2021 and later crashed -7975bps in 2022.
  • Tracing TXG's FCF Margin over 5 years: stood at 15.2% in 2021, then plummeted by -273bps to 56.74% in 2022, then surged by 165bps to 36.74% in 2023, then crashed by -97bps to 0.96% in 2024, then surged by 2463bps to 24.51% in 2025.
  • Business Quant data shows FCF Margin for TXG at 24.51% in Q4 2025, 31.24% in Q3 2025, and 9.33% in Q2 2025.